Digitalgene.AI Completes Pre-A Financing to Accelerate AI+RNA Dual-Driven Expansion in Pharma and Consumer Health

VCBeat has learned that Digitalgene.AI (Shanghai Digitalgene Information Technology Co., Ltd.), a tech startup offering an AI- and high-throughput experimentation-integrated platform for target discovery and RNA molecule design, has officially announced the completion of its Pre-A financing round. This round was led by a company listed on the STAR MarketCABIOLead Investor,CCMC Capital, Lingang Digital Technology Fund, Minjin Investment, Kangrong PharmaceuticalCo-investment.

Previously, the company completed its angel round of financing, with investors including K2VC and Yunqi Partners. To date, the company has raised a cumulative total of tens of millions of U.S. dollars, with a shareholder base comprising top-tier venture capital firms, industrial capital, and state-owned platforms, steadily enhancing its industry recognition.

The proceeds from this round of financing will be primarily used to accelerateAdvancement of the clinical pipeline, iteration of AI and high-throughput platforms, and expansion into the consumer-grade raw material market for siRNA,Propelling the company from the “platform capability validation phase” into the commercialization window period officially driven by the dual engines of “pharmaceuticals + consumer health.”

Digitalgene.AI OriginalAI Prediction + High-Throughput Experimental Validation"Dry-wet closed-loop" R&D model breaks the industry pain points of traditional RNA development, which relies on empirical trial-and-error and involves lengthy cycles, compressing the original 3–5 year R&D timeline to 6–9 months.

Meanwhile, the company has independently developed a multi-tissue RNA delivery system, overcoming two core challenges—RNA molecular stability and targeted delivery—thereby establishing a robust foundational technological barrier.

Digitalgene.AI has comprehensively laid out a multi-domain pipeline leveraging its technological achievements. In the field of serious medical care,Pulmonary Fibrosis PipelineNotably, leveraging the company’s proprietary AI platform to identify novel pathogenic targets, screen potential molecular structures, and advance them into human clinical trials. According to existing data,This molecule can significantly reverse the decline in lung function among patients with end-stage, untreatable clinical conditions—an effect that no other drug worldwide has achieved to date.

Meanwhile, the company has made in-depth strategic investments in the dermatology sector, covering multiple complex skin conditions such as psoriasis, atopic dermatitis, and melasma. It is also developing innovative pipelines in areas such as localized fat reduction and consumer healthcare, with several projects having entered the preclinical and early-stage R&D phases.

At the commercialization level, develop two benchmark core products in the whitening segmentKobainand in the field of anti-agingKesuoyin, take the leadAchieving a global first in the commercialization of siRNA-based skincare active ingredients.

Regarding the team, the company is headquartered in Shanghai with an R&D center in Beijing. Its core founding and scientific research teams hail from top-tier institutions such as Harvard University, Carnegie Mellon University, Tsinghua University, Shanghai Jiao Tong University, and the Chinese Academy of Sciences. More than half of the R&D personnel hold doctoral degrees. With years of deep expertise in the AI+RNA field, the team has published numerous findings in prestigious journals including Nature and Science, demonstrating robust and solid scientific research capabilities.

Regarding securing this round of financing,Yuan Ye, Founder of Digitalgene.AIDigitalgene.AI was born out of our long-term exploration into how “AI and programmable molecular technologies are reshaping biomedical R&D.” We have been dedicated to developing a closed-loop platform that integrates AI with high-throughput RNA technologies, reengineering the R&D processes for RNA therapeutics and high-value molecules. This approach establishes a new paradigm in RNA biopharmaceutical development, revolutionizing drug discovery by significantly accelerating timelines, reducing costs, and improving success rates. Targeting multiple multi-trillion-dollar markets with substantial unmet clinical needs, we are continuously developing innovative therapeutic molecules aimed at curing diseases, extending lifespan, and enhancing quality of life, thereby advancing our grand vision of global health and well-being.

Wu Yujun, General Manager of CABIO's Bio-industry InvestmentDigitalgene.AI has deeply cultivated the AI+RNA sector, establishing a rare technological moat. Centered on AI empowerment and RNA digitalization technologies, and integrating dermatological science, the company bridges two critical demand sectors: ingredients for efficacy-based cosmetics and treatments for skin diseases, demonstrating a highly forward-looking strategic layout. Leveraging large-model-based high-throughput screening, Digitalgene.AI has significantly enhanced target discovery efficiency and overcome the challenge of transdermal RNA delivery, setting a new industry benchmark. Its core ingredients already serve leading domestic and international brands, fully validating their commercial value and competitiveness.

The Company possesses the dual attributes of beauty consumption and dermatological healthcare, offering vast market potential. It leverages its platform to continuously deploy core and reserve pipelines. 2026 marks both the inaugural year of AI industrial applications and the Company’s first year of commercialization, as the synthetic biology “carbon-based revolution” and the artificial intelligence “silicon-based revolution” converge into a new era. As an industrial investor and strategic partner, CABIO has prioritized skin health as a key business segment. Digitalgene.AI aligns closely with CABIO’s strategy across technology, products, and commercialization scenarios. Together, CABIO and Digitalgene.AI are joining forces to accelerate commercial implementation. We look forward to the Company’s continued commitment to technological and business model innovation, jointly driving the future of the AI+RNA beauty and health industry.

Lingang Digital Science and Technology FundThe team stated that Digitalgene.AI is a high-quality sci-tech innovation enterprise in the Greater Lingang Bay area of Minhang District. Built on its core “AI+RNA” technology platform, the company has leveraged forward-looking industrial layout and sustained R&D investment to penetrate two critical application sectors: health-focused skincare and dermatological disease treatment. It has successfully established rare dual barriers in both technology and commerce within the industry, highlighting its comprehensive competitive strength and core industry advantages. The company’s self-developed core products have gained broad market recognition, with steadily improving reputation and commercial maturity, demonstrating strong growth potential in the fields of cosmetic efficacy enhancement and dermatological healthcare.

CCMC CapitalThe project leader stated: "Digitalgene.AI focuses on the intersection of AI and small nucleic acids, a field with broad commercialization prospects. Its product pipeline covers pharmaceuticals as well as cosmetics and medical aesthetics, representing significant market potential. The company possesses a leading technology platform capable of addressing multiple core challenges in small nucleic acid R&D, such as innovative target discovery and sequence design and modification. Meanwhile, its products have gained recognition from numerous industry partners. We look forward to Digitalgene.AI's rapid development in meeting more clinical and consumer needs."

Shanghai MinjintouThe team stated that AI for Science (AI4S) is profoundly reshaping the R&D paradigm for RNA therapeutics and functional molecules. The industry is gradually moving away from the traditional model reliant on extensive wet-lab experiments and iterative trial-and-error, transitioning instead into an intelligent, high-efficiency closed-loop R&D process characterized by AI-driven prediction, precise synthesis, and rapid validation. Digitalgene.AI has assembled top-tier scientific talent in the fields of AI and RNA to establish a comprehensive, end-to-end closed-loop R&D system covering target screening, molecular design, molecular modification, and efficacy validation. This approach effectively addresses the longstanding industry challenges of prolonged development cycles and high costs associated with traditional siRNA research, thereby building robust technical barriers and offering significant potential for commercial growth. We are optimistic about the company’s innovative foundation rooted in the “Grand Neo Bay” area and look forward to empowering the enterprise to accelerate technological iteration and market expansion. This will help propel core Chinese AI+RNA technologies to the forefront of the global industry and inject new momentum into the high-quality development of the regional artificial intelligence and biopharmaceutical sectors.

Investors in Guangdong Kangrong PharmaceuticalStatement: Leveraging its globally leading AI + high-throughput siRNA development platform, Digitalgene.AI has successfully achieved the commercial application of siRNA technology in cosmetic scenarios. Its independently developed products deliver significant skincare efficacy at ultra-low concentrations, demonstrating irreplaceable advantages in target precision, transdermal delivery efficiency, and skin safety. This represents another revolutionary breakthrough in the fields of beauty and skin health, following traditional active ingredients and peptide-based skincare. We believe that, backed by the team’s leading R&D capabilities and expertise in practical application, Digitalgene.AI will grow into a benchmark enterprise in the global AI+RNA skincare sector, spearheading a scientific revolution in the beauty industry. Meanwhile, Kangrong will fully leverage its nearly 30 years of resource accumulation, sterile formulation production experience, and industrial translation advantages in the health and efficacy-based skincare sectors to help Digitalgene.AI accelerate technological iteration, raw material implementation, and market expansion. Together, they will advance frontier biotechnologies such as AI+siRNA, providing consumers with safer, more efficient, and precise skincare solutions.